eClinical Solutions Appoints Three C-Suite Executives
eClinical Solutions appoints three C-suite executives to lead product, finance, and talent functions amid strong first-half momentum and market...
Editor's Choice
WCG launches Activation Intelligence to reduce clinical trial rework
WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites 20+ hours per study...
FL-020 Achieves 88% PSA50 Response in Phase 1 mCRPC Study
FL-020 achieves 88% PSA50 response in Phase 1 mCRPC study, including benefit in patients previously treated with lutetium-177.
ASP-1929 + Pembrolizumab Shows 28-Month Median OS in HNSCC Study
ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase 1b/2...
The Psilocybin Layer 5 Finding Changes How I Think About What We’re Actually Dosing For
A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape how we design...
When Payer Status Becomes a Protocol Variable: What the Medicare Advantage Transplant Gap Means for ESKD Trial Enrollment
MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a disparity that...
Pelacarsen Lowered the Biomarker. It Did Not Save Lives. Now What?
Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B assumption...
YPrime Names Greg Wellbrock Chief Data and AI Officer
YPrime names Greg Wellbrock Chief Data and AI Officer to lead unified data and AI strategy across its clinical...
Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials
Arcus Biosciences has $694M in cash to advance its pipeline through pivotal trials, including the Phase 3 PRISM-1 study...
Fifth Circuit Vacates Class Certification in Filana Therapeutics Securities Case
Fifth Circuit vacates class certification in Filana Therapeutics securities case, removing litigation overhang as company advances simufilam clinical program.